289MO Fruquintinib plus sintilimab in advanced cervical cancer (CC) patients (pts): Results from a multicenter, single-arm phase II study
Xian Wu(East Carolina University), Su Wang(Qingdao Center of Resource Chemistry and New Materials), Guozhong Li(Harbin Medical University), Ping Tan(Sichuan University), Xinwei Han(Columbia University Irving Medical Center), Hongzhe Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing Wang(Qingdao University), Dong Wang(Zhejiang Chinese Medical University), Jian Zhang(Zhujiang Hospital), Yu Kang(Tianjin University), Kun Wang(Union Hospital), Meiqi Shi(Jiangsu Cancer Hospital), Yan Huang(Qilu Hospital of Shandong University), Shanhui Fan(Stanford University), Tienan Yi(Xiangyang Central Hospital), Peihua Lu(Beijing Dao Pei Hospital), An-Bu Liu(Nanchang University)
Cited by 1
Related Papers
NF-κB in biology and targeted therapy: new insights and translational implications
|Signal Transduction and Targeted Therapy|2024|1.6k
Radiative cooling to deep sub-freezing temperatures through a 24-h day–night cycle
|Nature Communications|2016|854
Subambient daytime radiative cooling textile based on nanoprocessed silk
|Nature Nanotechnology|2021|463
Cytosolic escape of mitochondrial DNA triggers cGAS-STING-NLRP3 axis-dependent nucleus pulposus cell pyroptosis
|Experimental & Molecular Medicine|2022|321